The meteoric rise of injectable weight-loss medications, particularly semaglutide products, has taken the world by storm. Originally developed to help individuals with type 2 diabetes manage their blood sugar, these treatments have captured the public imagination for their potent role in weight management.
However, this skyrocketing demand has triggered a parallel, alarming trend: a surge in unregistered, improperly supplied products circulating outside official medical channels.
Recent regulatory concerns in South Africa have thrown a harsh spotlight on the profound health risks patients face when turning to unverified sources. With no registered generic semaglutide products currently on the South African market, desperate consumers are increasingly falling prey to sophisticated online marketing, social media sellers, and unauthorised wellness clinics.
The core danger for consumers lies in a false sense of security. Because semaglutide itself has been extensively studied and approved globally for specific medical uses, patients often assume that any product carrying the name is identical. Experts warn this is a perilous misconception.
Why injectables carry higher risk
The primary hazard does not stem from regulated semaglutide itself, but rather from unknown origins, a lack of regulatory assessment, and zero clinical oversight. Cindi Benjamin, pharmacovigilance and compliance pharmacist at Pharma Dynamics, emphasises that the critical distinction lies between products that have undergone formal regulatory review and those supplied outside established quality, safety, and monitoring systems.
“Patients may assume that all products marketed as semaglutide are equivalent, but that is simply not the case. A SAHPRA-approved medicine has undergone extensive evaluation for quality and efficacy,” says Benjamin.
“With unregistered products, there may be uncertainty around ingredients, sterility, potency, storage conditions and dose accuracy. These are particularly important considerations for injectable medicines.”
Related stories
- Ozempic: Diabetes drug becomes diet craze
- Why South Africans struggle to access Ozempic, Mounjaro
- Tired of weight gain? Boost your metabolism naturally
- Hoodia: The appetite-slaying, weight-loss plant
When a manufacturer seeks approval from the South African Health Products Regulatory Authority (SAHPRA), they must submit exhaustive evidence. This includes rigorous data on the active pharmaceutical ingredient, manufacturing processes, site quality controls, stability, labelling, and clinical efficacy.
For injectable medications, the stakes are exponentially higher. SAHPRA meticulously assesses:
- Sterility and purity: Unsterile injectables can introduce dangerous bacteria directly into the bloodstream or tissue, causing severe infections.
- Dose consistency: Inaccurate dosing can lead to accidental toxicity or render the treatment completely ineffective.
- Cold-chain integrity: Semaglutide requires strict temperature controls. If compromised during informal shipping or storage, the protein can degrade, become useless or trigger adverse immune responses.
International regulators have echoed these sentiments, explicitly cautioning both patients and healthcare professionals against the risks of compounded or unregistered semaglutide products due to rampant concerns around dosing accuracy.
Prioritising safety over convenience
The landscape is poised to evolve, with many pharmaceutical companies expected to enter the market in due course to expand patient access to registered, quality-assured medicines. Until then, bypassing the system for a “lower-cost” or “easier” alternative puts lives at risk. Standardised packaging and clear dosing instructions are vital safeguards; without them, the risk of severe adverse effects skyrockets.
Benjamin urges consumers to remain highly sceptical of products promoted through social media, online sellers, or unauthorised distributors.
“Patients may be attracted by lower prices or easier access, but they should first confirm that the product has undergone formal assessment for quality and efficacy, and that it can be appropriately traced and monitored should a safety concern arise.”
Cindi Benjamin
Essential guide for consumers:
- Prescription only: Only use semaglutide that is prescribed and dispensed through a recognised healthcare professional.
- Verify registration: Explicitly confirm with your pharmacist that the product is SAHPRA-registered.
- Block the black market: Avoid products sold via social media, wellness channels, or unverified online platforms.
Ultimately, patients must prioritise quality and safety over convenience, ensuring any medication used is backed by formal regulatory oversight.
ALSO LISTEN TO: Podcast: Lightening the load when it comes to weight
